QDEL
Price
$11.91Alerts
Change
+$0.39 (+3.39%)
Updated
Nov 11 closing price
Capitalization
733.76M
98 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$9.76Alerts
Change
+$0.06 (+0.62%)
Updated
Nov 11 closing price
Capitalization
1.89B
113 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

QDEL vs XRAY

QDEL vs XRAY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
QDEL vs. XRAY commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QDEL is a Hold and XRAY is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for QDEL with price predictions
Nov 10, 2026

QDEL in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2026

QDEL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 45 cases where QDEL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where QDEL's RSI Indicator exited the oversold zone, 34 of 44 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for QDEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +2.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 176 of 261 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.

The Aroon Indicator entered an Uptrend today. In 113 of 153 cases where QDEL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QDEL as a result. In 73 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for QDEL turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 36 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 75%.

QDEL moved below its 50-day moving average on November 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.413) is normal, around the industry mean (4.142). P/E Ratio (-0.693) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (40.124).

The Tickeron Seasonality Score of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. QDEL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for XRAY with price predictions
Nov 10, 2026

XRAY in upward trend: price rose above 50-day moving average on November 10, 2026

XRAY moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 55 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.

The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 30 of 53 cases over the following month. The odds of a continued upward trend are 57%.

The 10-day moving average for XRAY crossed bullishly above the 50-day moving average on November 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 5 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 45%.

Following a +2.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 174 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Bearish Trend Analysis

The 10-day RSI Indicator for XRAY moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 22 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 63 cases where XRAY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.

XRAY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.396) is normal, around the industry mean (4.964). P/E Ratio (-3.465) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.068) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
QDEL vs XRAY: Fundamental Ratings
QDEL
XRAY
OUTLOOK RATING
1..100
1718
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
6
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
6258
P/E GROWTH RATING
1..100
1315
SEASONALITY SCORE
1..100
4775

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (6) in the Medical Specialties industry is in the same range as QDEL (30). This means that XRAY’s stock grew similarly to QDEL’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as QDEL (100). This means that XRAY’s stock grew similarly to QDEL’s over the last 12 months.

XRAY's SMR Rating (97) in the Medical Specialties industry is in the same range as QDEL (98). This means that XRAY’s stock grew similarly to QDEL’s over the last 12 months.

XRAY's Price Growth Rating (58) in the Medical Specialties industry is in the same range as QDEL (62). This means that XRAY’s stock grew similarly to QDEL’s over the last 12 months.

QDEL's P/E Growth Rating (13) in the Medical Specialties industry is in the same range as XRAY (15). This means that QDEL’s stock grew similarly to XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QDELXRAY
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
60%
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
57%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
63%
Advances
ODDS (%)
Bullish Trend 8 days ago
67%
Bullish Trend 2 days ago
60%
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 6 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
75%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (QDEL: $11.52 vs. XRAY: $9.70)
Brand notoriety: QDEL and XRAY are both not notable
QDEL represents the Medical/Nursing Services, while XRAY is part of the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: QDEL: 107% vs. XRAY: 110%
Market capitalization -- QDEL: $733.76M vs. XRAY: $1.89B
QDEL [@Medical/Nursing Services] is valued at $733.76M. XRAY’s [@Pharmaceuticals: Other] market capitalization is $1.89B. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $159.96B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $9.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QDEL’s FA Score shows that 2 FA rating(s) are green while XRAY’s FA Score has 2 green FA rating(s).

  • QDEL’s FA Score: 2 green, 3 red.
  • XRAY’s FA Score: 2 green, 3 red.
According to our system of comparison, both QDEL and XRAY are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QDEL’s TA Score shows that 6 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).

  • QDEL’s TA Score: 6 bullish, 4 bearish.
  • XRAY’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, QDEL is a better buy in the short-term than XRAY.

Price Growth

QDEL (@Medical/Nursing Services) experienced а -18.24% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -0.31% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.

Reported Earning Dates

QDEL is expected to report earnings on Feb 17, 2027.

XRAY is expected to report earnings on Mar 04, 2027.

Industries' Descriptions

@Medical/Nursing Services (-2.89% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

@Pharmaceuticals: Other (+1.96% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
Interact to see
Advertisement

QDEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, QDEL has been loosely correlated with AZTA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if QDEL jumps, then AZTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QDEL
1D Price
Change %
QDEL100%
-4.71%
AZTA - QDEL
51%
Loosely correlated
-1.15%
XRAY - QDEL
50%
Loosely correlated
+1.68%
RVTY - QDEL
50%
Loosely correlated
-1.01%
DHR - QDEL
49%
Loosely correlated
+0.42%
A - QDEL
48%
Loosely correlated
-1.27%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+1.68%
NVST - XRAY
62%
Loosely correlated
-0.50%
ALGN - XRAY
59%
Loosely correlated
N/A
QDEL - XRAY
50%
Loosely correlated
-4.71%
KIDS - XRAY
48%
Loosely correlated
-1.50%
STE - XRAY
46%
Loosely correlated
+0.07%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CDIO1.860.06
+3.33%
Cardio Diagnostics Holdings Inc.
IEX236.900.97
+0.41%
IDEX Corp
NMIH38.73-0.14
-0.36%
NMI Holdings
GAIN15.01-0.08
-0.53%
Gladstone Investment Corp
AVXL1.13-0.09
-7.38%
Anavex Life Sciences Corp